Cargando…

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

The investigation of interleukin 1β (IL-1β) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti–human IL-1β antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1β–antibody complexes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lachmann, Helen J., Lowe, Philip, Felix, Sandra Daniela, Rordorf, Christiane, Leslie, Kieron, Madhoo, Sheril, Wittkowski, Helmut, Bek, Stephan, Hartmann, Nicole, Bosset, Sophie, Hawkins, Philip N., Jung, Thomas
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2009
Materias:	Brief Definitive Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715040/ https://www.ncbi.nlm.nih.gov/pubmed/19364880 http://dx.doi.org/10.1084/jem.20082481

Ejemplares similares

Neurology of the Cryopyrin-Associated Periodic Feversyndrome
por: Parker, T, et al.
Publicado: (2015)

Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response
por: Yu, Justin R., et al.
Publicado: (2010)

Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome
por: Stackowicz, Julien, et al.
Publicado: (2021)

Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System
por: Keddie, Stephen, et al.
Publicado: (2018)

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
por: Koné-Paut, Isabelle, et al.
Publicado: (2011)

Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome
por: Dhimolea, Eugen
Publicado: (2011)

The role of somatic NLRP3 mosaicism and new gene discovery in mutation negative cryopyrin-associated periodic syndrome patients
por: Gomes, Sonia Melo, et al.
Publicado: (2014)

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome
por: Elmi, Abdulkadir A., et al.
Publicado: (2019)

Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes
por: Bachove, Inessa, et al.
Publicado: (2014)

Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
por: Quartier, Pierre
Publicado: (2011)

Late onset of the cryopyrin-associated periodic syndrome (CAPS) associated with low level of somatic mosaicism in six patients
por: Rowczenio, D, et al.
Publicado: (2015)

Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism—UK Single Center Experience
por: Rowczenio, Dorota M., et al.
Publicado: (2017)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
por: Bibalo, C, et al.
Publicado: (2011)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013)

Evidence based recommendations for diagnosis and treatment of cryopyrin-associated periodic syndromes (CAPS)
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
por: Tilson, Hugh, et al.
Publicado: (2013)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

Erythema nodosum in an adolescent patient with cryopyrin‐associated periodic syndrome
por: Chan, Linda, et al.
Publicado: (2018)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

The First Case Series of Cryopyrin-Associated Periodic Syndrome in Korea
por: Han, Jong Hee, et al.
Publicado: (2019)

Most Important Factors in Diagnosing Cryopyrin-Associated Periodic Syndrome
por: Lee, Soyoung, et al.
Publicado: (2021)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra
por: Terrada, Celine, et al.
Publicado: (2011)

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
por: Bozkurt, Yasemin, et al.
Publicado: (2015)

Unified modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
por: Gul, A, et al.
Publicado: (2015)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
por: Chakraborty, Abhijit, et al.
Publicado: (2012)

Interleukine-6 and TNFα blockers provide only partial and short-term temporal improvement in cryopyrin-associated periodic syndrome
por: Dolgikh, Vladimir, et al.
Publicado: (2014)

Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome
por: Kawai, Mariko, et al.
Publicado: (2013)

Cryopyrin‐associated periodic syndrome with inflammatory bowel disease: A case study
por: Raymond, Karen N, et al.
Publicado: (2021)

Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
por: Kullenberg, Torbjörn, et al.
Publicado: (2016)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

PReS-FINAL-2234: Successful canakunimab treatment in uveitis secondary to cryopyrin-associated periodic syndrome
por: Kasapcopur, O, et al.
Publicado: (2013)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Differences in disease activity in cryopyrin-associated periodic syndrome in mutation-positive and mutation-negative patients
por: Kostik, M, et al.
Publicado: (2015)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021)

Lessons From the Misdiagnosis of Cryopyrin-Associated Periodic Syndrome as an Infection: Importance of an Early and Precise Diagnosis
por: Li, Tao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mb2kab2lrke5vmb6rtbqiali6v